| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-07-22 | Covidien (Ireland) | president | nomination | Medical devices | Nomination | |
| 2014-07-21 | Arena Pharmaceuticals (USA - CA) Abic Marketing, Teva Pharmaceutical Industries Limited\'s subsidiary (Israel) | BELVIQ® (lorcaserin HCl) | weight loss or weight management in obese and overweight patients | commercialisation supply |
Metabolic diseases | Commercialisation agreement |
| 2014-07-21 | Basilea Pharmaceutica (Switzerland) Quintiles (USA - NC) | Zevtera®/Mabelio® (ceftobiprole medocaril) | severe community-acquired and hospital-acquired pneumonia | commercialisation |
Infectious diseases | Commercialisation agreement |
| 2014-07-21 | Medical Research Council (MRC), AstraZeneca (UK), GSK (UK), Janssen Research & Development, Janssen Research & Development, a J&J company (USA -NJ), Eli Lilly (USA- IN), Pfizer (USA - NY), Takeda (Japan), UCB (Belgium) | collaboration |
Collaboration agreement | |||
| 2014-07-17 | Nicox (France) Immco Diagnostics (USA) | Sjö™ laboratory test | Sjögren’s Syndrome | commercialisation |
Autoimmune diseases - Ophtalmological diseases | Licensing agreement |
| 2014-07-17 | Helsinn (Switzerland) Chugai Pharmaceutical (Japan) | oral fixed-dose combination capsule of netupitant 300 mg + palonosetron 0.50 mg (NEPA) | prevention of chemotherapy-induced nausea and vomiting (CINV) | commercialisation |
Cancer - Oncology - CNS diseases | Commercialisation agreement |
| 2014-07-16 | Eli Lilly (USA -IN) Immunocore (UK) | T cell-based cancer therapies using ImmTAC technology | R&D development |
Cancer - Oncology | R&D agreement | |
| 2014-07-16 | Mymetics (Switzerland) Imugene (Australia) | cancer immunotherapy HER-Vaxx | manufacturing production |
Cancer - Oncology | Production agreement | |
| 2014-07-16 | bluebird bio (USA - MA) | Rare diseases - Genetic diseases | Nomination | |||
| 2014-07-16 | BiogenIdec (USA - MA) Yahoo Health (USA - CA) | MS Visionaries™ program | mutliple sclerosis | collaboration |
Autoimmune diseases - Neurodegenerative diseases | Collaboration agreement |
| 2014-07-15 | LEO Pharma (Denmark) KLOX Technologies (Canada) | BioPhotonic technology platform including a CE approved treatment for moderate to severe acne | acne | licensing joint-venture |
Dermatological diseases | Joint-venture agreement |
| 2014-07-15 | Novartis (Switzerland) Banner Alzheimer\'s Institute (USA - Denmark) | investigational anti-amyloid treatments (BACE inhibitor and active immunotherapy) | Alzheimer’s disease | collaboration clinical research |
Neurodegenerative diseases | Clinical research agreement |
| 2014-07-15 | Alcon (USA), a Novartis subsidiary (Switzerland) Google (USA - CA) | smart lens technology | collaboration |
Ophtalmological diseases - Metabolic diseases | Collaboration agreement | |
| 2014-07-14 | Anthera Pharmaceuticals (USA - CA), Eli Lilly (USA - IN) | Sollpura® (liprotamase) | Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases | product acquisition |
Pancreatic diseases - Metabolic diseases - Rare diseases | Product acquisition |
| 2014-07-14 | GSK (UK) Codexis (USA - CA) | CodeEvolver® protein engineering platform technology | licensing |
Technology - Services | Licensing agreement | |
| 2014-07-14 | Zeltia (Spain) Pharma Mar (Spain) Chugai Pharmaceutical (Japan) | Aplidin® (plitidepsin) | multiple myeloma | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-07-14 | A*STAR’s Bioprocessing Technology Institute (BTI) (Singapore) Roche (Switzerland) | novel drug candidates for the detection and treatment of cancer | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-07-14 | PharmaMar, Zeltia Group (Spain) Chugai Pharmaceutical (Japan) | Aplidin® (plitidepsin) | multiple myeloma | licensing |
Cancer - Oncology - Rare diseases | Licensing agreement |
| 2014-07-10 | Nestlé (Switzerland) Valeant Pharmaceuticals (Canada) | Restylane®, Perlane®, Emervel®, Dysport®, Sculptra® | product acquisition |
Aesthetic medicine - Dermatological diseases | Product acquisition | |
| 2014-07-09 | Paion (Germany), Pendopharm (Canada) | remimazolam | sedation, general anaesthesia | licensing development commercialisation |
CNS diseases | Licensing agreement |
